CDTX / Cidara Therapeutics: FDA Approval Dead Ahead

Shares of Cidara Therapeutics soared 18.5% in early New York trading, buoyed by news that Janssen Pharmaceuticals, a subsidiary of healthcare giant Jo more_horizontal

Cidara Therapeutics is a biotech company with an approved antifungal drug, Rezzayo, but its sales are not enough to offset expenses. The company's pip more_horizontal

Cidara Therapeutics (CDTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to more_horizontal

With their first product approval last quarter, Europe should follow suit. Their U.S. partner is experienced in commercializing antibiotics. more_horizontal

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the n more_horizontal

Cidara Therapeutics (NASDAQ: CDTX ) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. The big FDA new more_horizontal

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics des more_horizontal

Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an more_horizontal